ARTICLE | Kx Advisors, part of BGBx Consulting Beyond C5: Complement Inhibition Is Moving Toward Lower-Burden, Disease-Specific Approaches A pipeline analysis of rare-disease complement therapeutics, from preclinical development through...
Read More